Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech (AIM) reported third-quarter financials on November 13, 2020. Cash and equivalents surged to $54.5 million from $8.8 million at year-end 2019. Research expenses fell slightly to $1.10 million, while general expenses rose to $2.09 million. Clinically, AIM revealed promising pancreatic cancer survival data, with median survival improving by 200% for patients treated with Ampligen compared to historical controls. Additionally, significant findings were reported for ME/CFS and COVID-19, with Ampligen showing potential benefits for early-stage patients.
AIM ImmunoTech announced the publication of significant data indicating that its drug Ampligen may effectively treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when used early. The research, published in PLOS ONE, revealed that 51.2% of Ampligen-treated ME/CFS patients improved their exercise duration by at least 25%. The company has expanded its AMP-511 Early Access Program to include 'Long Haulers' from COVID-19, suggesting a potential benefit from early treatment. Amidst this, AIM emphasizes the need for further research to validate these findings.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels will participate in a virtual panel titled “COVID-19: Progress on Treatments & Prevention” on October 29 at 10:05 A.M. ET during the 23rd Annual BioFlorida Conference. The conference will feature discussions by global experts on BioPharma, MedTech, HealthIT, and COVID-19. Attendees can access the live webcast via the conference platform. AIM ImmunoTech is dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech has received IRB approval for an expanded access clinical trial of Ampligen to treat chronic fatigue-like symptoms in COVID-19 patients, also known as Long Haulers. The updated protocol allows for 20 out of 100 participants to include those who have been diagnosed with SARS-CoV-2 but still show symptoms. AIM anticipates a rise in Chronic Fatigue Syndrome (CFS) cases post-COVID-19 and is preparing to submit the IRB-approved protocol to the FDA. This also follows a provisional patent application for Ampligen as a therapy for COVID-19-induced ME/CFS-like illnesses.
AIM ImmunoTech announced statistically significant positive results in pancreatic cancer survival from an Early Access Program at Erasmus University Medical Center. The median survival increased by approximately 200% for patients treated with Ampligen compared to historical controls. AIM aims to seek FDA Fast Track designation and orphan drug status for Ampligen as a treatment for late-stage pancreatic cancer. The company will collaborate with Amarex Clinical Research to initiate a Phase 2/3 clinical trial in the Netherlands and the U.S., seeking to extend exclusivity rights for Ampligen.
AIM ImmunoTech Inc. (NYSE American:AIM) announced the start of recruitment for a Phase 1/2a clinical trial at Roswell Park Comprehensive Cancer Center. The trial investigates the use of rintatolimod (Ampligen) combined with interferon alpha-2b for cancer patients with mild to moderate COVID-19. This study aims to leverage 20 years of cancer immunotherapy research to engage the innate immune system against SARS-CoV-2 and other RNA viruses. The trial is funded with support from the National Cancer Institute and AIM.
AIM ImmunoTech Inc. (NYSE American:AIM) will present at the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO Thomas K. Equels is set to deliver a presentation on September 14 at 5:00 p.m. ET, which will be available via live webcast. The company focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American:AIM) announced that CEO Thomas K. Equels will participate in the virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs" on September 10, 2020, at 1:00 p.m. ET. The panel features executives from prominent biopharmaceutical firms discussing their strategies to combat the COVID-19 pandemic. Moderated by journalist Christine Corrado, the event aims to inform investors about advancements in treatment. AIM is known for its research in immune disorders and viral diseases, particularly for its key products, Ampligen® and Alferon N Injection®.
AIM ImmunoTech Inc. (NYSE American:AIM) announced a promising breakthrough in combating SARS-CoV-2, demonstrating that Ampligen, a dsRNA TLR3 agonist, reduced infectious viral yields by 90% in an in vitro model. This result supports the potential of Ampligen as an intranasal prophylactic treatment for COVID-19. CEO Thomas K. Equels expressed optimism about these findings, highlighting the need for further human testing. The company aims to advance clinical trials based on these results, although it notes the requirement for substantial additional research to confirm effectiveness in human subjects.
AIM ImmunoTech (NYSE American:AIM) announced its participation in The LD 500 Investor conference, taking place virtually from September 1-4, 2020. CEO Thomas K. Equels is scheduled to present on September 1st at 1:20 p.m. Eastern Time. The presentation will be live-streamed on the event's platform. One-on-one meetings with AIM are available through video calls. The LD 500 features prominent small and micro-cap companies, along with keynotes from industry leaders. Interested parties can register via provided links or contact details.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
